Sanwa Kagaku Kenkyusho Obtains Manufacturing Approval for Sable, Postprandial Glucose Controlling Agent.Tokyo, Japan, Oct 15, 2005 - (JCNN JCNN Japan Corporate News Network ) - Sanwa Kagaku Kenkyusho, a subsidiary of Suzuken, announced on October 11 that it has received manufacturing approval for Sable (miglitol), its proprietary agent for controlling postprandial postprandial /post·pran·di·al/ (-pran´de-al) occurring after a meal. post·pran·di·al adj. Following a meal, especially dinner. glucose level in diabetics, from the Ministry of Health, Labor and Welfare. After listing on the NHI NHI abbr. National Health Insurance drug price list, the company will promote the agent in collaboration with Dainippon Sumitomo Pharmaceutical. The company will offer three dosage forms: 25mg, 50mg and 75mg. The newly-approved agent, which was developed by a German company Bayer Healthcare, is currently marketed in 29 countries worldwide. Source: JCN JCN Japan Corporate News JCN Journal of Cognitive Neuroscience JCN Journal of Cardiovascular Nursing JCN Journal of Christian Nursing JCN Job Control Number JCN Journal of Child Neurology JCN joint communications network (US DoD) http://www.japancorp.net Copyright [c] 2005 Japan Corporate News Network. All rights reserved. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion